Search for: "Arp v. Arp"
Results 1 - 20
of 375
Sorted by Relevance
|
Sort by Date
17 May 2024, 9:37 pm
Cir. 1997) and Epcon Gas Sys., Inc. v. [read post]
24 Nov 2018, 12:52 pm
General Observations About the Work Streams V. [read post]
20 Sep 2011, 6:32 am
In a recent en banc decision by the Delaware Supreme Court in CML V, LLC v. [read post]
23 Jul 2015, 8:02 am
The litigation involves a contract attorney suing Skadden Arps and... [read post]
5 Sep 2010, 8:41 am
When Courts and Congress Don’t Say What They Mean: Initial Reactions to Morrison v. [read post]
3 Feb 2012, 7:08 am
Editor’s Note: The following post comes to us from Brian V. [read post]
9 Apr 2008, 8:27 am
Per Kimble v. [read post]
15 Feb 2012, 6:52 am
John Fund, Inc. v. [read post]
17 Mar 2012, 4:37 am
Editor’s Note: The following post comes to us from Brian V. [read post]
15 Oct 2011, 7:04 am
Editor’s Note: The following post comes to us from Brian V. [read post]
20 Apr 2014, 4:00 am
Sivia v. [read post]
10 Jun 2024, 12:43 am
§ 112(a))Enablement was considered by the US Supreme Court in Amgen v Sanofi, with respect to an antibody genus claim. [read post]
11 Jul 2008, 9:13 am
Ending a six-week doll-fight that included a lawyer-squabble over historic hotel rooms, lawyers from Quinn Emanuel and Skadden Arps faced off for the final time yesterday in the case of Mattel v. [read post]
9 Nov 2008, 1:20 pm
On October 22, 2008, Vice Chancellor Lamb of the Delaware Court of Chancery issued an opinion in Olson v. [read post]
7 Jan 2016, 2:51 pm
In Arp v. [read post]
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
